ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Phase C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will obtain ABBV-744 and ruxolitinib. Contributors will receive treatment until finally condition progression or the individuals are unable to tolerate the study drugs.Total, our recent work highlights the potential utilization of ARV-825 in combination with